Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal

被引：2
|
作者：
Usmani, S. Z. [1 ]
Hoering, A. [2 ]
机构：
[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
[2] Canc Res & Biostat, Seattle, WA USA
来源：
LEUKEMIA | 2013年 / 27卷 / 12期
关键词：
TOTAL THERAPY 3; MULTIPLE-MYELOMA; BORTEZOMIB; DELETION;
D O I：
10.1038/leu.2013.161
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2269 / 2271
页数：3
相关论文
共 50 条
  • [1] Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal
    S Z Usmani
    A Hoering
    [J]. Leukemia, 2013, 27 : 2269 - 2271
  • [2] Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
    Harvey, R. Donald
    [J]. CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2014, 6 : 87 - 96
  • [3] Management of Hematologic Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Nooka, Ajay K.
    [J]. ONCOLOGY-NEW YORK, 2013, 27 : 11 - 18
  • [4] Incidence and Management of Renal Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Shah, Jatin J.
    [J]. ONCOLOGY-NEW YORK, 2013, 27 : 19 - 23
  • [5] Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase ll trials
    Siegel, D.
    Martin, T.
    Nooka, A.
    Harvey, R. D.
    Vij, R.
    Niesvizky, R.
    Badros, A. Z.
    Jagannath, S.
    McCulloch, L.
    Rajangam, K.
    Lenial, S.
    [J]. ONKOLOGIE, 2013, 36 : 39 - 40
  • [6] Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma
    Nooka, Ajay K.
    Badros, Ashraf Z.
    Patel, Priti
    McCulloch, Leanne
    Lonial, Sagar
    Kaufman, Jonathan L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase 2 trials
    Siegel, D. S.
    Martin, T.
    Nooka, A.
    Harvey, R. D.
    Vij, R.
    Niesvizky, R.
    Badros, A. Z.
    Jagannath, S.
    McCulloch, L.
    Rajangam, K.
    Lonial, S.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 20 - 20
  • [8] Overview and Management of Cardiac and Pulmonary Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Wang, Michael
    Cheng, Jie
    [J]. ONCOLOGY-NEW YORK, 2013, 27 : 24 - 30
  • [9] Single-agent Aredia for relapsed/refractory multiple myeloma.
    Berenson, JR
    Webb, IJ
    Anderson, K
    Schlossman, R
    Vescio, R
    Doss, D
    Goon, B
    Swift, R
    VonTeichert, J
    Kowalski, M
    Seaman, J
    [J]. BLOOD, 1999, 94 (10) : 307B - 307B
  • [10] HEMATOLOGIC SAFETY PROFILE OF SINGLE-AGENT CARFILZOMIB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA FROM FOUR PHASE 2 STUDIES
    Nooka, A.
    [J]. HAEMATOLOGICA, 2012, 97 : 601 - 601
12345